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Lifetime risks data were extrapolated from a published Markov
model. Screening and population data were extracted from ofﬁ-
cial references. Costing was assessed through the compiled 5 year
activities of a gynaecologic department (CHUV, Lausanne),
TARMED (2005) and Compendium (2005). Sensitivity analyses
examined vaccine parameters, range of treatment patterns and
costs. RESULTS: For a 12 year old cohort of girls with 40%
vaccine coverage rate, the model predicts a lifetime reduction of
22% of CC and related deaths, −23% of CIN 2/3, −11% for
CIN 1 and −36% for genital warts. The associated increase in
the national health care budget was only 3% (+4,5 million CHF).
If vaccine coverage rate reached 80%, clinical impact on CC
would be more than 50% better whilst increasing the budget by
only 6%. Results are robust to sensitivity analyses. CONCLU-
SION: Preventing HPV related diseases through vaccination with
a quadrivalent (6, 11, 16, 18) HPV vaccine alongside CC screen-
ing in Switzerland could result in signiﬁcant clinical beneﬁts with
only a slight increase on the national health care budget.
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OBJECTIVES: To assess the potential epidemiological, clinical,
and economic effects of different varicella vaccination strategies
in Italy, involving children and adolescents. METHODS: The
simulation model EVITA (Banz et al. 2003) was developed to
analyse universal varicella vaccination strategies. Epidemiologi-
cal and economic model input data were collected from Tuscany
region data banks and the available Italian literature. The vac-
cination strategies analysed included: 1) 1–1.5 y (years), 85%
coverage; 2) 1–1.5 y + catch-up 12 y (1 dose, 30% catch-up cov-
erage); 3) 1–1.5 y + catch-up 13 y (2 doses, 30% coverage); and
4) 1–1.5 y with 2 doses + catch-up 13 y (2 doses, 30% coverage).
Analysis time horizon was 30 years. RESULTS: Without univer-
sal vaccination, the model predicted 501.644 varicella cases and
27.341 related complications in Italy each year. All vaccination
strategies resulted in excellent clinical outcomes, with strategy 2)
being the most effective, preventing over 83% of varicella cases
and complications. A low coverage scenario (50%) prevented
only 68% of varicella cases, with a rebound of cases occurring
after around 15 years of initial decline. Average yearly cost
savings for strategy 2) are 62 million Euros for the society and 2.3
million Euros for the NHS, and for the 1) strategy 59.7 and 2.5
million Euros, respectively. The most favourable clinical and eco-
nomic outcomes of a catch-up programme occurred when vac-
cinating 12 y adolescents with 1 dose instead 13 y adolescents
with 2 doses. Only strategy 4) failed to generate savings for the
NHS. No signiﬁcant differences in outcomes were detected when
using epidemiological and seroprevalence data corresponding to
North, Centre and South of Italy. CONCLUSIONS: Universal
varicella vaccination in children (with or without an adolescent
catch-up programme) is very effective in reducing the high
burden of disease and leads to signiﬁcant cost savings.
PIN3
COST–EFFECTIVNESS ANALYSIS OF TONSILOPHARYNGITIS
AND RHYNOPHARINGITIS ACCUTA,ANTIBIOTIC
TREATMANT, SRBIJA, NIS REGION
Mihajlovic MM1, Nikolic S2
1City Pharmacy Nis, Nis,Yugoslavia, 2Government Primary Health
Care Institution, Nis, Serbia, Serbia and Montenegro
OBJECTIVES: Identiﬁcation of cost–effectivness antibiotic treat-
ment method tonsilopharyngitis and rhynopharingitis accuta in
pediatric population from just born to 12 years old children in
which these diagnosis were establish on the level of private and
government primary health care practice system, depending of
clinical report and possible drug hypersensitivity. METHODS:
Cost–effectiveness analysis was done in two different periods of
time; The ﬁrst one was before establishing “The National guide
for antibiotic treatment”, and the second one after that. Four
possible treatments with 30 children each were observed. These
are following–before the implementation of the National guide
1) Phenoxymethylpenicillin oral suspension (300,000 IJ/5 ml 10
days); 2) Erythtomycin oral suspension (200 mg/5 ml 5 days); 3)
Benzylpenicilin procainpennicillin inj i.m. (800,000 IJ 7 days); 4)
Lincomycin inj i.m (600 mg/2 ml 7 days). After 1) Amoxicilin +
clavulonic acid oral suspension (7 days); 2) Azirohromycin oral
suspension (200 mg/5 ml 4 days), 3) Benzylpenicillin procain-
penicillin inj i.m.; 4) Phenoxymethlpenicillin oral suspension.
Real costs were calculated for each possible treatment contains
direct (ﬁrst doctor visit, control check up, medicines and OTC
therapy costs), indirect (additional treatment payment and even-
tual complication payment). Patients were sorted in those with
completely, partly successful and total unsuccessful treatment.
ICER (Incremental cost effectivness ratio) was deﬁned for each
possible treatment; base was number of days without refreshing
infection. Comparison of ICER value gave cost effectivness
therapy. RESULTS: ICER showed for the ﬁrst period that Ben-
zylpenicillin procainpenicillin inj i.m. (7 days) was the best cost
effectivness treatment. In addition The National guide conﬁrmed
and recommended it also. On the contrary, after implementation
of the National guide the most prescribing treatments were
Amoxicilin+clavulonic acid oral suspension (7 days) and Phe-
noxymethlpenicillin oral suspension (10 days). It doesn’t reduce
therapy costs. CONCLUSIONS: Prescribing practice in Serbia
should be changed by using the most CE methods and that will
cause decrease in total costs of antibiotic therapy.
PIN4
ANTIBIOTIC THERAPY OF NOSOCOMIAL INFECTION IN THE
INTENSIVE CARE UNIT: A COST-EFFECTIVENESS ANALYSIS
Kulikov A, Krysanov I, Lomakin A
Moscow Medical Academy, Moscow, Russia
OBJECTIVES: To determine the cost-effectiveness of meropenem
treatment versus standard strategy of antibiotic (AB) therapy for
high-risk patients with nosocomial infection (NI) in the intensive
care unit (ICU). METHODS: Two group high-risk patients with
NI were randomly assigned to AB treatment: 1st—62 pts received
meropenem (1.5–3 g daily) and 2nd—73 pts treated by standard
AB therapy (combination of penicillins with or without a beta-
lactamase inhibitor, cephalosporins III or IV generation, ﬂuoro-
quinolons with aminoglicosides). Direct medical costs (cost of
drag administration, resource utilization, duration of hospital-
ization) were estimated. Achievement of recovery was used as
effectiveness. Unit costs were based on detailed data from the
Moscow Obligatory Insurance Fond (2006). The rate of exchange
was 34,44 rubles for 1 EUR. RESULTS: Direct medical costs were
1618.6 EUR for group 1 (C1) and 2065.7 EUR for group 2 (C2).
Achievement of recovery −80.6% (E1) and 46.6% (E2) for each
group respectively, p < 0,01. The ﬁnal calculation of cost/effec-
tiveness ratio (CER) was: CER1 = €20.08 and CER2 = €44.32
per every percent of recovered patients for group 1 and 2 respec-
tively. CONCLUSION: Meropenem usage versus standard AB
therapy is more effective from the position “cost-effectiveness”
in the treatment of high-risk patients with nosocomial infection
in the intensive care unit.
